- Home
- XGN vs CATX Comparison
XGN vs CATX Comparison
Compare XGN & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- CATX
- Stock Information
- Founded
- XGN 2002
- CATX 1983
- Country
- XGN United States
- CATX United States
- Employees
- XGN N/A
- CATX N/A
- Industry
- XGN Medical Specialities
- CATX Medical/Dental Instruments
- Sector
- XGN Health Care
- CATX Health Care
- Exchange
- XGN Nasdaq
- CATX Nasdaq
- Market Cap
- XGN 253.9M
- CATX 239.0M
- IPO Year
- XGN 2019
- CATX N/A
- Fundamental
- Price
- XGN $7.47
- CATX $2.17
- Analyst Decision
- XGN Strong Buy
- CATX Strong Buy
- Analyst Count
- XGN 6
- CATX 10
- Target Price
- XGN $13.67
- CATX $11.00
- AVG Volume (30 Days)
- XGN 460.9K
- CATX 1.9M
- Earning Date
- XGN 11-04-2025
- CATX 11-10-2025
- Dividend Yield
- XGN N/A
- CATX N/A
- EPS Growth
- XGN N/A
- CATX N/A
- EPS
- XGN N/A
- CATX N/A
- Revenue
- XGN $63,599,000.00
- CATX $1,075,000.00
- Revenue This Year
- XGN $22.50
- CATX N/A
- Revenue Next Year
- XGN $14.75
- CATX N/A
- P/E Ratio
- XGN N/A
- CATX N/A
- Revenue Growth
- XGN 14.08
- CATX N/A
- 52 Week Low
- XGN $2.67
- CATX $1.60
- 52 Week High
- XGN $12.23
- CATX $5.39
- Technical
- Relative Strength Index (RSI)
- XGN 18.36
- CATX 35.67
- Support Level
- XGN $9.19
- CATX $1.96
- Resistance Level
- XGN $8.35
- CATX $2.54
- Average True Range (ATR)
- XGN 0.59
- CATX 0.20
- MACD
- XGN -0.27
- CATX 0.03
- Stochastic Oscillator
- XGN 0.59
- CATX 34.19
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.